Jeffrey R. Infante, Tony R. Reid, Allen L. Cohn, William J. Edenfield, Terrence P. Cescon, John T. Hamm, Imtiaz A. Malik, Thomas A. Rado, Philip J. McGee, Donald A. Richards, Jamal Tarazi, Brad Rosbrook, Sinil Kim and Thomas H. Cartwright Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study Cancer 119
Version of Record online: 19 APR 2013 | DOI: 10.1002/cncr.28112
This randomized, phase 2 trial shows that objective response rates and progression-free and overall survival are numerically inferior in patients who receive axitinib plus combined 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-6) versus bevacizumab plus FOLFOX-6. Shorter treatment duration and more discontinuations because of adverse events observed in the axitinib arm suggest that vascular endothelial growth factor receptor tyrosine kinase inhibitors plus chemotherapy may be somewhat less well tolerated than bevacizumab plus chemotherapy.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field